LOVELAND, Colo., March 6, 2012 /PRNewswire/ -- Heska
Corporation (NASDAQ: HSKA), a provider of advanced veterinary
diagnostic and other specialty veterinary products, today announced
that The Patent Board, a leading independent provider of best
practices research, tools and metrics for patent analysis and
intellectual property investment (http://www.patentboard.com), has
again ranked Heska's Science Strength in the top 50 of the
Biotechnology industry.
The Patent Board's ranking evaluates patents issued or applied
for over the last 12 months. This is the second consecutive
ranking by The Patent Board of Heska's IP portfolio. More
information can be found online at www.PatentBoard.com.
"We are pleased to once again have our intellectual property
and, accordingly, our scientific innovation recognized by a
respected third party," said Dr. Robert
Grieve, Heska's Chairman and CEO. "Heska's founding value
was predicated on great science in important markets. Execution of
that science led to substantial proprietary intellectual property;
the quality of these assets may often be overlooked. Much of
this foundational intellectual property is applicable to markets of
parasite prevention and control, the largest markets in animal
health. Heska will continue to work to find the right opportunities
to unlock this value, most likely some form of an alliance with a
company that has access to pharmaceutical discovery resources and a
commitment to parasite control markets."
As of February 29, 2012, Heska
owns, co-owns or has rights to 184 issued U.S. patents and three
pending U.S. patent applications with a corresponding foreign
patent portfolio including 131 issued patents and 15 pending patent
applications in various foreign countries. Heska's issued and
pending patent portfolios primarily relate to heartworm control,
flea control, allergy, infectious disease vaccines, diagnostic and
detection tests, immunomodulators, instrumentation, nutrition, pain
control and vaccine delivery technologies.
About Heska
Heska Corporation (NASDAQ: HSKA) sells advanced veterinary
diagnostic and other specialty veterinary products. Heska's
state-of-the-art offerings to its customers include diagnostic
instruments and supplies as well as single use, point-of-care
tests, pharmaceuticals and vaccines. The Company's core focus
is on the canine and feline markets where it strives to provide
high value products and unparalleled customer support to
veterinarians. For further information on Heska and its products,
visit the company's website at www.heska.com.
About The Patent Board
Founded in 1968 as a patent analytics and research institution,
The Patent Board is the leading independent provider of best
practices research, tools and metrics for patent analysis and
intellectual property investment. The Patent Board tracks and
analyzes innovation, movement, and the business value of patent
assets across every industry on a global basis. Visit
www.PatentBoard.com for more information.
Forward-Looking Statements
This announcement contains forward-looking statements
regarding Heska's future financial and operating
results. These statements are based on current expectations
and are subject to a number of risks and
uncertainties. Investors should note there is a risk is using
the rating system of any third party when evaluating intellectual
property as this is a complex endeavor and the ratings obtained may
not be consistent with future commercial results. In addition,
factors that could affect the business and financial results of
Heska generally include the following: uncertainties regarding the
value any third party would place on Heska's patent portfolio;
uncertainties regarding Heska's ability to form an alliance with a
pharmaceutical company or any third party, as well as uncertainties
regarding the ultimate success of such an endeavor; risks related
to Heska's ability to legally enforce its patents; uncertainties
related to reliance on a third party to commercialize Heska's
intellectual property; competition, including the impact of new
products competitors may introduce in the future; and the risks set
forth in Heska's filings and future filings with the Securities and
Exchange Commission, including those set forth in Heska's Annual
Report on Form 10-K for the year ended December 31, 2011.
SOURCE Heska Corporation